Merck announces third-quarter 2026 financial results and pipeline updates
Sales rose 5% to $18.1 billion, driven by KEYTRUDA growth, while the company raises full-year outlook.
Latest Merck News & Updates
See the latest news and media coverage for Merck. We track all announcements, press releases, and industry mentions in real time, all in one place.
Research-intensive biopharmaceutical company
merck.com- Headquarters
- Rahway, United States
- Company type
- Public company
- Number of employees
- 44,000+
- Industry
- Pharmaceuticals
Last updated
Latest news about Merck
In short: Merck raised its 2026 outlook after third-quarter sales rose 5% to $18.1 billion.
Company announcements
Merck sac-TMT reduces death risk by 32% in endometrial cancer patients
TroFuse-005 phase 3 data show improved survival vs chemotherapy. FDA accepted BLA for priority review with PDUFA date June 15, 2027.
Merck and Moderna present positive Phase 3 INTerpath-001 trial results for melanoma treatment
The combination of intismeran autogene plus KEYTRUDA significantly reduced recurrence risk by 42% compared to KEYTRUDA alone in stage IIB-IV melanoma patients, with benefits increasing after six months.
Merck secures European Commission approval for KEYTRUDA plus Padcev regimen
This first-in-class perioperative treatment for muscle-invasive bladder cancer covers all EU states and applies to patients regardless of cisplatin eligibility.
Media coverage
Merck Boosts FY26 Outlook - Update
For fiscal 2026, Merck now projects adjusted earnings in a range of $2.77 to $2.82 per share on sales between $66.8 billion and $67.3 billion...
Merck plans investment to offset Keytruda cliff
Merck executives highlight pipeline wins and strong sales for subcutaneous Keytruda and Winrevair while preparing for the looming patent expiry of its blockbuster cancer therapy.
Merck tops third-quarter estimates as Keytruda, Gardasil outperform
Merck posted higher-than-expected third-quarter earnings on Thursday, driven by strong demand for it...
ESMO: In sac-TMT’s first global phase 3 win, Merck sees ‘pretty consistent’ data with China
As a cornerstone of Merck & Co.’s post-Keytruda oncology strategy, sac-TMT has cleared a clinical milestone. | As a ...
Never miss news about Merck
Track Merck and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Merck competitors & trending companies
Browse news for competitors to Merck and other trending companies.